Clinical trials for Multiple myeloma
62 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 2
Multiple myeloma
#NCT05572229
#2022-001594-31
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
17 recruiting sites
Hôpital universitaire de Lille
Phase 1 / Phase 2
Multiple myeloma
#NCT06953960
#2024-517140-65-00
Sous étude 1 Escalade de dose
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required genetic anomalies
t(11;14)
Required number of previous lines of therapy
3 or more
Required previous treatments
Monoclonal antibodies
Proteasome inhibitor
Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
Abbvie
Phase 1 / Phase 2
Multiple myeloma
#NCT06953960
#2024-517140-65-00
Sous-étude 1 Cohorte Expansion et sélection de dose
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required genetic anomalies
t(11;14)
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
Proteasome inhibitor
Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
Abbvie
Phase 1 / Phase 2
Multiple myeloma
#NCT04643002
#2020-003024-16
Sous-étude 02
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
2
3 or more
Required previous treatments
Proteasome inhibitor
Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
Sanofi
Phase 1 / Phase 2
Multiple myeloma
#NCT04643002
#2020-003024-16
Sous-étude 05
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
2
3 or more
Required previous treatments
Monoclonal antibodies
Proteasome inhibitor
Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
Sanofi
Phase 1 / Phase 2
Multiple myeloma
#NCT04643002
#2020-003024-16
Sous-étude 01
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
2
3 or more
Required previous treatments
Proteasome inhibitor
Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
Sanofi
Phase 1 / Phase 2
Multiple myeloma
#NCT04643002
#2020-003024-16
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
2
3 or more
Required previous treatments
Proteasome inhibitor
Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
Sanofi
Phase 1 / Phase 2
Multiple myeloma
#NCT04643002
#2020-003024-16
Sous-étude 04
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
2
3 or more
Required previous treatments
Monoclonal antibodies
Proteasome inhibitor
Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
Allogeneic stem cell transplant
4 recruiting sites
Sanofi
Phase 1 / Phase 2
Multiple myeloma
#NCT04643002
#2020-003024-16
Sous-étude 06
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
2
3 or more
Required previous treatments
Proteasome inhibitor
Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
Allogeneic stem cell transplant
4 recruiting sites
Sanofi
Phase 1 / Phase 2
Multiple myeloma
#NCT04973605
#2023-507751-30-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required genetic anomalies
t(11;14)
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
BeOne Medecines